# Arboretum LifeSciences

> Molecular-information company expanding genetic testing and precision medicine into common diseases.

## Why it is interesting

It combines a clinical testing network with a longer-term strategy to acquire and spin out therapeutics matched to genetic profiles.

## Profile

- **Latest funding:** Series A — $30M (October 6, 2026)
- **Latest known valuation:** Undisclosed (October 6, 2026)
- **Total disclosed equity funding:** $30M
- **Stage:** series-a
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech, ai-ml
- **Coverage:** full
- **Last updated:** 2026-10-08T02:35:00Z
- **Latest funding investors:** F-Prime Capital, GV, .406 Ventures, Hims & Hers, Amgen

## Key facts

- Launched with a $30M Series A.
- Targets cardiovascular, metabolic and neurodegenerative conditions beyond oncology and rare disease.

## Funding history

- Series A · $30M · October 6, 2026
  Source: https://www.financialcontent.com/article/bizwire-2026-10-6-arboretum-launches-to-redefine-precision-medicine-for-common-diseases-as-a-next-generation-molecular-information-company

## Investors in our directory

- https://venturecapitaltracker.com/fund/f-prime-capital
- https://venturecapitaltracker.com/fund/gv

## Related articles

- https://venturecapitaltracker.com/2026-namespace-clockwork-arboretum-200m-funding-roundup

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 8, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/arboretum-lifesciences